Lannett Announces Addition To Management Team

PHILADELPHIA, Feb. 23, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that Kristin A. Arnold, Ph.D., has joined the company as vice president of research and development, effective February 27, 2017. 

"As head of research and development (R&D), Kristin will be responsible for leading all of Lannett's research and product development efforts," said Arthur Bedrosian, chief executive officer of Lannett. "Kristin will work in collaboration with our senior leadership to further build and enhance our drug portfolio and R&D organization.  I have great confidence that Kristin will help position Lannett for continued growth and success."

Prior to joining Lannett, Dr. Arnold served as vice president product development and technical services for Norwich Pharmaceuticals Inc., where she led a team of specialists that developed the CMC sections of regulatory submissions and oversaw the company's project management function from inception through product launch. Earlier in her career, she rose through the senior management ranks of URL Pharma/Mutual Pharmaceutical Company, most recently as senior vice president product development. Before that, Dr. Arnold was senior director product development for Alpharma/Purepac and manager formulations for FMC Corporation and Ecogen, Inc. Before that, she served as a team leader, research specialist and senior research chemist at Monsanto. Dr. Arnold earned a doctoral degree in physical organic chemistry from the University of Miami, Coral Gables, Florida and a bachelor of arts degree in chemistry, A.C.S. certified, from La Salle University.

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

SOURCE Lannett Company